After an $80M Series D raise, DalCor takes another shot at a PhIII myocardial infarction trial

Ayisha Sharma

News Reporter

DalCor Pharmaceuticals has regrouped from past setbacks to complete an $80 million Series D round to advance its cholesteryl ester transfer protein (CETP) inhibitor, dalcetrapib …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After an $80M Series D raise, DalCor takes another shot at a PhIII myocardial infarction trial

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Af­ter an $80M Se­ries D raise, Dal­Cor takes an­oth­er shot at a PhI­II my­ocar­dial in­farc­tion tri­al

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

After an $80M Series D raise, DalCor takes another shot at a PhIII myocardial infarction trial